Tectonic Therapeutics: Currently In A Catalyst Vacuum

2026-05-19 13:42:03 ET

Shares of cardiac medicine concern Tectonic Therapeutics, Inc. ( TECX ) have fallen roughly ~40% since hitting an all-time high in January 2025, as concerns about other failures of other relaxins weigh. Results from a Phase 2 heart failure trial for its candidate TX45 are due at year end 2026, with management trusting it identified why inefficacy impelled Eli Lilly ( LLY ) to terminate its relaxin analog program. Pursuing a multi-billion-dollar PH-HFpEF indication featuring a patient population of ~1.4 million Americans with no approved remedies, the recent price action in Tectonic merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: